Characteristics
All patients (n= 108) Female (n= 31) Male (n= 77)
P value
Age,years 57 (53-66) 56 (52-64) 57 (55-68) 0.659
Histology Clear cell Non-clear cell 78 (72.2%) 30 (27.8 %) 27(87%) 4 (13%) 57 (74%) 20 (26%)
0.734
Metastatic region sites 1-2 3-4-5 88 (81.5%) 20 (18.5%) 24 (81.5%) 7 (18.5%) 64 (81.5%) 13 (18.5%)
0.490
Tumor Grade I II III IV 5 (4.6%) 20 (18.6%) 37 (34.3%) 46 (42.5%) 3 (4%) 5 (17.8%) 11 (34.7%) 11 (43.6%) 2 (2.5%) 15 (19.4%) 26 (33.7%) 35 (45.4%)
0.622
Treatment type Pazopanib Sunitinib 64 (59.3%) 44 (40.7%) 17 (54.8%) 14 (45.2%) 47 (61%) 30 (39%)
0.553
IMDC risk group Favorable Intermediate Poor 9 (8.3%) 66 (61.1%) 33 (30.5%) 3 (9.6%) 19 (61.2%) 9 (29%) 6 (7.7%) 47 (61%) 24 (31.1%)
1